Mark Wilson, Principal, Strategic Technology Bioconsulting, Healthcare Specialist, Global Corporate Venturing
Mark Wilson is a consultant in the field of technology commercialisation, with twenty years’ experience of developing, commercialising and licensing novel technologies. He acts as an adviser and interim business development director to European biotech firms, is engaged in academic research on the changing nature of corporate venture capital in the life science industries, and is developing a corporate VC summit for Global Corporate Venturing. Previously, he was a Director in GSK’s Platform Technology and Science division, seconded on a long-term basis into SR One (GSK’s wholly-owned corporate venture capital group). He was responsible for developing technology-based spin-outs and for out-licensing activity, and co-led this CEO-sponsored initiative. Mark worked for GSK in various licensing and alliance management roles for over fifteen years and has been involved in over a hundred commercial transactions and alliances. He holds a Master’s degree and a doctorate in chemical engineering from the University of Leeds, in addition to an MBA from Columbia University and London Business School.